Barclays’s Adamas Pharmaceuticals ADMS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-11,279
| Closed | -$56K | – | 4952 |
|
|
2021
Q3 | $56K | Buy |
11,279
+5,546
| +97% | +$26.9K | ﹤0.01% | 4086 |
|
|
2021
Q2 | $30K | Buy |
5,733
+4,595
| +404% | +$23.8K | ﹤0.01% | 4373 |
|
|
2021
Q1 | $5K | Buy |
+1,138
| New | +$5.94K | ﹤0.01% | 4491 |
|
|
2020
Q3 | – | Sell |
-6,135
| Closed | -$16K | – | 5764 |
|
|
2020
Q2 | $16K | Sell |
6,135
-1,509
| -20% | -$4.43K | ﹤0.01% | 5252 |
|
|
2020
Q1 | $22K | Sell |
7,644
-15,795
| -67% | -$70.8K | ﹤0.01% | 5618 |
|
|
2019
Q4 | $90K | Buy |
23,439
+10,494
| +81% | +$50.2K | ﹤0.01% | 5528 |
|
|
2019
Q3 | $66K | Sell |
12,945
-2,726
| -17% | -$16.8K | ﹤0.01% | 5763 |
|
|
2019
Q2 | $97K | Sell |
15,671
-35,175
| -69% | -$202K | ﹤0.01% | 5719 |
|
|
2019
Q1 | $362K | Buy |
50,846
+33,459
| +192% | +$301K | ﹤0.01% | 4373 |
|
|
2018
Q4 | $148K | Buy |
17,387
+8,118
| +88% | +$106K | ﹤0.01% | 4786 |
|
|
2018
Q3 | $186K | Sell |
9,269
-77,146
| -89% | -$1.81M | ﹤0.01% | 5064 |
|
|
2018
Q2 | $2.23M | Buy |
86,415
+74,723
| +639% | +$2.07M | ﹤0.01% | 2489 |
|
|
2018
Q1 | $279K | Buy |
11,692
+9,319
| +393% | +$294K | ﹤0.01% | 4532 |
|
|
2017
Q4 | $80K | Sell |
2,373
-1,888
| -44% | -$52.7K | ﹤0.01% | 5417 |
|
|
2017
Q3 | $90K | Buy |
4,261
+131
| +3% | +$2.4K | ﹤0.01% | 4996 |
|
|
2017
Q2 | $72K | Buy |
4,130
+3,893
| +1,643% | +$64.4K | ﹤0.01% | 5130 |
|
|
2017
Q1 | $4K | Sell |
237
-3,721
| -94% | -$63.4K | ﹤0.01% | 6354 |
|
|
2016
Q4 | $66K | Buy |
3,958
+3,750
| +1,803% | +$58K | ﹤0.01% | 4997 |
|
|
2016
Q3 | $3K | Sell |
208
-60
| -22% | -$912 | ﹤0.01% | 6178 |
|
|
2016
Q2 | $4K | Buy |
268
+34
| +15% | +$561 | ﹤0.01% | 5821 |
|
|
2016
Q1 | $3K | Sell |
234
-55
| -19% | -$926 | ﹤0.01% | 5824 |
|
|
2015
Q4 | $8K | Buy |
289
+234
| +425% | +$3.94K | ﹤0.01% | 5471 |
|
|
2015
Q3 | $1K | Sell |
55
-144
| -72% | -$3.28K | ﹤0.01% | 6658 |
|
|
2015
Q2 | $5K | Buy |
199
+112
| +129% | +$2.18K | ﹤0.01% | 6488 |
|
|
2015
Q1 | $1K | Sell |
87
-150
| -63% | -$2.57K | ﹤0.01% | 7003 |
|
|
2014
Q4 | $4K | Buy |
237
+207
| +690% | +$3.14K | ﹤0.01% | 7029 |
|
|
2014
Q3 | $1K | Sell |
30
-34
| -53% | -$585 | ﹤0.01% | 7555 |
|
|
2014
Q2 | $1K | Buy |
+64
| New | +$1.15K | ﹤0.01% | 7538 |
|
Barclays's ADMS Position: Q4 2021 in Review
Barclays sold out of Adamas Pharmaceuticals (ADMS) in Q4 2021, closing a stake of 11,279 shares — an estimated $56K sold.
Barclays first reported a position in ADMS in Q2 2014 and held it in 28 quarters. The position peaked at $2.23M in Q2 2018. 0 funds tracked by Wall St. Rank hold ADMS as of Q4 2021.
- Barclays reported no remaining Adamas Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
- Barclays sold 11,279 Adamas Pharmaceuticals shares in Q4 2021, an estimated $56K.
- Barclays first reported a position in Adamas Pharmaceuticals in Q2 2014 and held it in 28 quarters.
- Barclays's Adamas Pharmaceuticals position peaked at $2.23M in Q2 2018.
- 0 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2021.
Based on Barclays's 13F filing for Q4 2021, filed 14 Feb 2022.